Astrana Health Inc. · NASDAQ:ASTH

Astrana Health — Apollo Medical Holdings — Investor Presentation (September 2021)

46 slides from Astrana Health's investor presentation, Sep 9, 2021

  1. Slide 1: Apollo Medical Holdings September 2021

    Apollo Medical Holdings (NASDAQ:AMEH) September 2021 Powered by Technology. Built by Doctors. For Patients.

  2. Slide 2: Forward-looking statements

    Forward - looking statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward - looking statements include any statements about t he Comp

  3. Slide 3: ApolloMed At-A-Glance

    Apollo Medical Holdings, Inc. (“ApolloMed”) is a leading physician - centric, technology - powered, risk - bearing healthcare company. Leveraging its proprietary end - to - end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully

  4. Slide 4: Shift from fee-for-service to value-based care

    Value - based care Fee - for - service CMS, COVID - 19, payer contracting, and focus on quality while lowering total cost are driving shift in healthcare Fee - for - service Value - based care Lack of incentives to improve chronic health conditions Driving a trend of rapidly increasing medical costs

  5. Slide 5: Providers recognize value-based care but do not feel equipped

    Providers recognize the criticality of value - based care, but do not feel equipped to successfully navigate its complexities Recognize they will need to adopt value based model Indicated collecting and reporting the information for these quality measures is burdensome Would need additional resource

  6. Slide 6: Enables providers to successfully take risk

    Enables providers to successfully take risk • We believe that providers are the most suited to drive patient behavior, outcomes, and therefore total cost of care • We enable and onboard providers at scale to succeed in value - based care arrangements , aligning financial and clinical outcomes • Our

  7. Slide 7: We act as a single-payer and assume risk for patient care

    We act as a “single - payer” and assume risk for comprehensive patient care Insurance provider Insurance provider Insurance provider Other Payers Primary care provider Specialist services Lab tests Imaging Savings shared with providers, remaining retained as profit • 25+ yrs of operational expertise

  8. Slide 8: Long-term relationships with a diversified payer mix

    We have established long - term relationships with a diversified payer mix Average tenure with key payers 8 15 years Contribution from each top payer <15% total net revenue www.apollomed.net

  9. Slide 9: ApolloMed is profitable with attractive unit economics

    ApolloMed is profitable with attractive unit economics… www.apollomed.net 9 1 2 3 ApolloMed’s scale, extensive experience in value - based care, and better risk adjustment result in better per member per month payments vs industry standard 1 Our large network of physicians across primary care and va

  10. Slide 10: Additional value created as we grow

    ​ Increased capitation due to contracting and risk adjustment ​ Better specialty network cost management ​ Additional service lines ​ Reduced outsourced MSO fees ​ Improved quality of care bonus realization ​ Total improvement potential ​ Shared with physicians ​ Net savings to AMEH …and we consiste

  11. Slide 11: Proven model of consistent growth in members and physicians

    In addition to having a proven model of consistent growth across our members and physicians… www.apollomed.net 11 2,500 0 1,500 500 1,000 2,000 780 Members (in thousands) 384 2021E 2014 2017 1,130 2020 2,000 20% 77% 1,000 4,000 7,000 10,000 0 2,000 4,000 6,000 8,000 10,000 12,000 Contracted Physicia

  12. Slide 12: Next-Gen ACO demonstrated sustainable success

    …our Next - Gen ACO has demonstrated sustainable success, proving our ability to deliver savings and quality in value - based agreements www.apollomed.net 12 23,177 27,529 30,740 0 10,000 20,000 30,000 40,000 2017 Total aligned b eneficiaries 2018 2019 0 5 10 15 20 25 30 35 40 45 50 Total benchmark

  13. Slide 13: Provider network and tech platform drive a virtuous cycle

    ApolloMed’s large provider network and proprietary tech platform drive a virtuous cycle, powering growth and improving patient outcomes www.apollomed.net 13 Better outcomes increases value - based incentive payout and decreases utilization Machine learning models improve with more data Providers suc

  14. Slide 14: Platform enables improved outcomes for members

    Platform enables demonstrable improved outcomes for members 14 Medicare All information provided is 2019 data unless otherwise noted. Sources: CMS, Chronic Conditions Data Warehouse (CCW), competitors’ IR, and internal figures Hospital Admits per 1,000 Benchmark 274 137 197 Competitor 50% fewer ER V

  15. Slide 15: ApolloMed engine driven by proprietary tech platform

    ApolloMed engine driven by our proprietary tech platform 15 ApolloMed combines technology and data analytics, powered by machine learning and artificial intelligence, with clinical expertise Technology expertise + = Operational excellence Clinical knowledge Artificial intelligence Machine learning N

  16. Slide 16: Technology drives operational and clinical efficiency

    Technology drives operational and clinical efficiency 16 Our solutions address three key pain points in managed healthcare delivery: Automated medical claims adjudication Utilization management automation Population health and provider incentive platform • Have processed >4 million claims with no hu

  17. Slide 17: The Market Opportunity

    ApolloMed is at the intersection of provider services and healthcare technology, uniquely positioning it to grow rapidly The Market Opportunity 17

  18. Slide 18: ApolloMed is executing a clear growth strategy

    ApolloMed is executing a clear growth strategy 18 www.apollomed.net Consolidate additional IPAs and enter new markets and geographies Build on ACO success and participate in additional Innovation Models Continue to invest in technology, preventive care, and automation to further drive clinical care

  19. Slide 19: A significant market opportunity in provider services

    A significant market opportunity in provider services 19 (1) Source: CMS.gov – NHE Fact Sheet, physician and clinical services expenditures (2) Source: CHCF.org – California Personal Health Core Spending, 2017 – Quick Reference Guide U.S. serviceable addressable market for provider services Estimate

  20. Slide 20: Foothold in CA and 9 of top 25 counties

    Although we have established a strong foothold in CA and are already in 9 of the top 25 counties by population in the U.S… 20 NJ MD Served by ApolloMed IPAs Served by ApolloMed ACO Planned expansion www.apollomed.net

  21. Slide 21: Pursuing growth in the $3.6T provider services market

    …we are actively pursuing growth opportunities to capture greater share of the $3.6T provider services market opportunity 21 Current 2021 Goal ~1.1M Managed lives +500k >2M Managed lives +500k Managed lives in CA Managed lives outside of CA V V Provider services p opulation includes: Medicare , Medi

  22. Slide 22: Integration of acquired IPAs

    Integration of acquired IPAs 22 Allied Pacific IPA acquired for approx. $45M in May 2019 Allied Pacific IPA acquired remaining 75% stake not already held for approx. $7.25M in August 2019 ApolloMed continues to implement processes to fully integrate the IPAs acquired in 2019 into its framework — exp

  23. Slide 23: Strategic investment in CAIPA MSO – New York

    • CAIPA is a leading independent practice association serving the greater New York City area • Provides management, consulting, administrative, and other support services to professional healthcare service providers, including to Chinese American IPA d/b/a Coalition of Asian - American IPA (“CAIPA”)

  24. Slide 24: ApolloMed has overwhelming advantages

    24 Large and rapidly growing market opportunity in value - based care Profitable & proven model with predictable, attractive unit economics and upside from risk - sharing Scalable and repeatable playbook for hypergrowth Industry - leading technology driven by data moat Flywheel effect that exponenti

  25. Slide 25: Peer comparison

    Ticker NASDAQ: AMEH NASDAQ: PRVA NYSE: AGL NYSE: CANO NASDAQ: CLOV NYSE: OSH NASDAQ: ONEM Business Physician - centric, technology - powered healthcare company enabling providers in the successful delivery of value - based care Technology - driven, national physician enablement company that collabor

  26. Slide 26: Financial Overview

    Financial Overview A History of Profitable Growth

  27. Slide 27: Historical financial profile

    $10.8 $14.1 $37.9 $53.0 2018 2019 2020 2021* $520 $561 $687 $710 Historical revenue growth ($ in millions) * midpoint of 2021 guidance range ($ in millions) Historical financial profile www.apollomed.net * midpoint of 2021 guidance range 27 Historical net income attributable to ApolloMed growth 2018

  28. Slide 28: Summary of selected financial results

    www.apollomed.net 28 $ in 000s except per share data Q2 2021 Q2 2020 1H 2021 1H 2020 Revenue Capitation, net $ 144,550 $ 140,949 $ 289,290 $ 281,370 Risk pool settlements and incentives 16,214 12,003 34,224 23,239 Management fee income 8,143 8,690 16,693 17,505 Fee - for - service, net 4,621 2,270 7

  29. Slide 29: Updated 2021 guidance

    Updated 2021 guidance 29 www.apollomed.net $ in millions 2021 Guidance Range (as of March 10, 2021) 2021 Guidance Range (as of August 5, 2021) Total Revenue $690.0 - $710.0 $700.0 - $720.0 Net Income (1) $50.0 - $60.0 $56.0 - $66.0 Net Income Attributable to ApolloMed $35.0 - $45.0 $48.0 - $58.0 EBI

  30. Slide 30: Revenue breakdown

    Capitation - Capitated fees for medical services via direct arrangements with managed care providers . Typically pre - paid monthly based on number of enrollees Risk p ool s ettlements & i ncentives - Full and shared risk capitation arrangements with certain health plans , local hospitals and Next G

  31. Slide 31: Business mix by payer type

    www.apollomed.net 31 37% 39% 19% 5% Q2 2021 (% OF TOTAL REVENUE) Medicare Medicaid Commercial Other Third Parties Business mix by payer type

  32. Slide 32: Balance sheet highlights

    Balance sheet highlights 32 www.apollomed.net $ in millions 6/30/2021 12/31/2020 $ Change % Change Cash and cash equivalents and investments in marketable securities $364.5 $261.2 $103.3 40% Working capital $342.5 $223.6 $118.9 53% Total stockholders’ equity $404.6 $330.9 $73.7 22%

  33. Slide 33: Current capitalization

    Current capitalization 33 www.apollomed.net Note: Balance sheet data as of 6 /3 0 /202 1 (1) Excludes restricted cash of $88.9mm. (figures in millions, except per share price) Recent Share Price (as of 9w/2/2021) $ 79.49 Common Shares Outstanding 55.3 Market Capitalization $ 4,395.8 Plus: Total Bank

  34. Slide 34: Appendix

    Appendix 6) apollomed

  35. Slide 35: Organizational overview

    Together with our affiliated physician groups and consolidated entities, ApolloMed manages the medical lives of more than 1.1 million members. Consolidated IPAs ~ 558 ,000 member lives Publicly traded parent company M anagement services organization (MSO) Leading California IPAs * Managed IPAs ~ 484

  36. Slide 36: Management – A team of industry veterans

    Management – A team of industry veterans 36 Executive Chairman & Co - CEO Co - CEO & President Chief Operating Officer & Chief Technology Officer Chief Financial Officer Chief Administrative Officer Chief Quality Officer • Joined AMEH in 2006 • Currently serves as Chairman of Allied Pacific IPA, Cha

  37. Slide 37: Our service offerings & revenue model

    Across all aspects of care delivery, our offerings provide a steady revenue stream Our service offerings & revenue model 37 Consolidated Independent Practice Associations (IPAs) Next Generation ACO / Risk Model Management Services Organization (MSO) Commercial EPO Commercial ACO • Network of primary

  38. Slide 38: Stellar NGACO performance in 2019

    19.8 13.3 Stellar NGACO performance in 2019 www.apollomed.net 38 Net shared savings from CMS 37.3 Gross savings generated 19.8 17.5 Cap/risk arrangement 6.5 Provider bonus 13.3 Net shared savings settlement realized in Q3 2020 For the 2019 performance year, APA ACO was among the top 4 NGACOs in the

  39. Slide 39: Reconciliation of net income to EBITDA and Adjusted EBITDA

    Reconciliation of net income to EBITDA and Adjusted EBITDA 39 www.apollomed.net Q2 2021 Q2 2020 1H 2021 1H 2020 Net income $ 59.5 $ 81.0 $ 74.0 $ 84.0 Interest expense 1.9 2.7 3.4 5.5 Interest income (0.6) (0.9) (0.9) (1.8) Provision for income taxes 24.9 31.9 31.7 33.5 Depreciation and amortization

  40. Slide 40: TTM EBITDA reconciliation

    TTM EBITDA reconciliation 40 www.apollomed.net $ in millions Q3 2020 Q4 2020 Q1 2021 Q2 2021 TTM 2021* Net income $ 25.4 $ 12.9 $ 14.4 $ 59.5 $ 112.2 Interest expense 2.5 1.5 1.5 1.9 7.4 Interest income (0.8) (0.2) (0.3) (0.5) (1.8) Provision for income taxes 10.8 11.9 6.8 24.9 54.4 Depreciation and

  41. Slide 41: Guidance reconciliation of net income to EBITDA (August 2021)

    Guidance reconciliation of net income to EBITDA and Adjusted EBITDA 41 www.apollomed.net ($ in millions) Low High Net income $ 56.0 $ 66.0 Interest expense 6.0 8.4 Interest income (1.5) (2.4) Provision for income taxes 24.0 29.0 Depreciation and amortization 15.5 18.0 EBITDA $ 100.0 $ 119.0 Income f

  42. Slide 42: Guidance reconciliation of net income to EBITDA (March 2021)

    Guidance reconciliation of net income to EBITDA and Adjusted EBITDA 42 www.apollomed.net ($ in millions) Low High Net income $ 50.0 $ 60.0 Interest expense 8.0 8.5 Interest income (3.0) (5.0) Provision for income taxes 23.0 24.0 Depreciation and amortization 17.0 17.5 EBITDA $ 95.0 $ 105.0 Income fr

  43. Slide 43: Use of non-GAAP financial measures

    Use of non - GAAP financial measures This presentation contains the non - GAAP financial measures Earnings Before Interest, Taxes, Depreciation and Amortization (“EBIT DA”) and Adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with GAAP is net (loss) in

  44. Slide 44: Outstanding shares explained

    (1) The number of weighted average shares used to calculate EPS for the six months ended June 30, 2021, was approximately 44. 4 m illion. (2) Based upon information publicly available as of 8/6/2021. Outstanding shares explained 44 In December 2020, approx. 5 million of Allied Pacific IPA’s shares o

  45. Slide 45: Key acronyms

    Key acronyms 45 ◦ ACO: Accountable Care Organization ◦ AIPBP: All - Inclusive Population - Based Payments ◦ APC: Allied Physicians of California IPA ◦ CMMI: Center for Medicare and Medicaid Innovation ◦ CMS: Centers for Medicare & Medicaid Services ◦ DME: Durable Medical Equipment ◦ Health Plan / Pa

  46. Slide 46: Investor relations contact

    For inquiries, please contact: ApolloMed Investor Relations (626) 943 - 6491 investors@apollomed.net Carolyne Sohn, The Equity Group (415) 568 - 2255 csohn@equityny.com

Apollo Medical Holdings — Investor Presentation (September 2021) on 6ix